Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
American Journal of Clinical Oncology|October 8, 2008
A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignanciesLaura W Goff, Mace L Rothenberg, A Craig Lockhart, et al.
Investigational New Drugs|March 30, 2017
Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRASEmily Chan, Laura W Goff, Dana B Cardin, et al.
American Journal of Clinical Oncology|March 17, 2017
A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic CancerDana B Cardin, Ramya Thota, Laura W Goff, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 25, 2019
Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?Mina F Nordness, Stephanie Hamel, Caroline M Godfrey, et al.
Investigational New Drugs|October 10, 2017
Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trialDana B Cardin, Laura W Goff, Emily Chan, et al.
Investigational New Drugs|September 22, 2010
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabineLaura W Goff, Al B Benson, Patricia M LoRusso, et al.
Annals of Emergency Medicine|June 25, 2022
Catching Those Who Fall Through the Cracks: Integrating a Follow-Up Process for Emergency Department Patients with Incidental Radiologic FindingsTyler W Barrett, Nicholas M Garland, Clifford L Freeman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2015
A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid TumorsLaura W Goff, Roger B Cohen, Jordan D Berlin, et al.
Cancer Medicine|October 10, 2025
End-Of-Life Outcomes and Healthcare Utilization for Patients With Hepatocellular Carcinoma Who Received Immune Checkpoint InhibitionMargaret C Wheless, Anna-Carson R Uhelski, Sarah K Cimino, et al.
Investigational New Drugs|October 19, 2018
Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
Pageof 4